3Luvero D, Milani A, Ledermann JA. Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. TherAdv Med Onco12014; 6: 229-239.
4Zsiros E, Tanyi J, Balint K, Kandalaft LE. Immunotherapy for ovarian cancer: recent advances and perspectives. CurrOpin 0ncol2014; 26: 492-500.
5Yigit R, Massuger LF, Figdor CG, Torensma R. Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Onco12010; 117: 366-372.
6Facciabene A, Motz GT, Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res 2012; 72: 2162-2171.
7Viehl CT, Moore TT, Liyanage UK, Frey DM, Ehlers JP, Eberlein TJ et al. Depletion of CD4+CD25+ regulatory T cells promotes a tumor- specific immune response in pancreas cancer-bearing mice. Ann Surg 0ncol2006; 13: 1252-1258.
8Liu S, Foulkes WD, Leung S, Gao D, Lau S, Kos Z et al. Prognostic significance of FOXP3+ tumor infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration. Breast Cancer Res 2014; 16: 432..
9Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Onco12009; 27: 186-192.
10Kiniwa Y, Miyahara Y, Wang HY, Peng W, Peng G, Wheeler TM et al. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Research 2007; 13: 6947-6958.
